Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
Long-term glycaemic control with metformin-sulphonylurea-pioglitazone triple therapy in PROactive (PROactive 17)
The phase 2 NEJM trial (Jastreboff et al., 2023) enrolled 338 adults with obesity or overweight without type 2 diabetes over a 48-week treatment period
Diabetes 69 , 25892602 (2020)
The information in this comparison chart is based on the best available data as of June 2026
With a wealth of data in support of its safety and efficacy, semaglutide stands out among the breakthrough antiobesity drugs that have emerged in response to the obesity epidemic
In most cases, these reactions are self-limited and improve with proper site rotation and injection technique
US$ 28.66
US$ 24.87
US$ 29.76
US$ 24.90
